ReviewRevista medica del Instituto Mexicano del Seguro Social2025
[Multiple sclerosis and the Epstein-Barr Virus: Current perspectives on their pathogenic mechanisms].
Review in Revista medica del Instituto Mexicano del Seguro Social, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Epstein-Barr virus (EBV) is a herpesvirus that infects more than 90% of the world's population and is implicated in various diseases, including lymphoproliferative and neoplastic disorders. Recently, evidence has suggested a strong association between EBV and multiple sclerosis (MS). Although EBV infection is common, only a minority of carriers develop MS, indicating the influence of genetic and environmental factors in the pathogenesis. This article reviews the molecular mechanisms through which EBV might influence the development of MS. One mechanism discussed is molecular mimicry, where the similarity between EBV viral antigens and central nervous system proteins could induce a cross-reactive autoimmune response. Additionally, the mechanisms by which EBV evades the immune response are reviewed, including the expression of proteins such as EBNA1 and EBNA2, which interfere with the function of T and NK cells. Genetic factors, such as the HLA-DRB1*15:01 allele, a principal risk factor for MS, are also reviewed. This allele acts as a co-receptor facilitating the infection of B cells by EBV, which could explain the increased susceptibility to MS in individuals with this allele. Furthermore, EBV may alter the epigenetic regulation of genes associated with MS, affecting the expression of key genes in immune response and inflammation. Finally, immunotherapies targeting EBV, such as those based on cytotoxic T lymphocytes, are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.